[Safety monitoring and countermeasures of anticoagulant drugs for pulmonary thromboembolism].

Abstract

The safe use of anticoagulant drugs is a major challenge in the clinical management of pulmonary thromboembolism (PTE). This paper presents a comprehensive review of the recent literature, summarizing and evaluating the classification and historical development of anticoagulants, monitoring strategies for their administration, selection and safety considerations for special patient populations (such as those with malignant tumors, pregnant women or obese patients) and specific disease states (including platelet disorders, severe renal insufficiency, active bleeding and pulmonary hypertension). It also discusses current research into countermeasures for anticoagulant-related bleeding. Based on personal experience and expertise in this field, we propose an approach to managing the safety of anticoagulant therapy.